Squarepoint Ops LLC trimmed its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 22.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 694,180 shares of the company’s stock after selling 204,276 shares during the quarter. Squarepoint Ops LLC owned about 0.84% of Editas Medicine worth $3,242,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Koss Olinger Consulting LLC acquired a new position in shares of Editas Medicine during the 2nd quarter valued at about $47,000. Hoylecohen LLC bought a new stake in shares of Editas Medicine during the 2nd quarter worth $55,000. Spectrum Planning & Advisory Services Inc. acquired a new position in Editas Medicine in the 2nd quarter valued at $57,000. Aries Wealth Management bought a new position in Editas Medicine in the 2nd quarter worth $65,000. Finally, Headlands Technologies LLC lifted its position in Editas Medicine by 481.7% during the 1st quarter. Headlands Technologies LLC now owns 9,493 shares of the company’s stock worth $70,000 after acquiring an additional 7,861 shares during the last quarter. 71.90% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Editas Medicine news, EVP Linda Burkly sold 11,886 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $5.42, for a total value of $64,422.12. Following the sale, the executive vice president now directly owns 73,136 shares in the company, valued at $396,397.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Baisong Mei sold 6,619 shares of the firm’s stock in a transaction that occurred on Friday, July 19th. The shares were sold at an average price of $5.21, for a total transaction of $34,484.99. Following the completion of the sale, the executive vice president now owns 134,413 shares of the company’s stock, valued at $700,291.73. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Linda Burkly sold 11,886 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $5.42, for a total value of $64,422.12. Following the completion of the transaction, the executive vice president now directly owns 73,136 shares in the company, valued at $396,397.12. The disclosure for this sale can be found here. Insiders sold 20,578 shares of company stock worth $105,997 in the last 90 days. 1.90% of the stock is owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Research Report on EDIT
Editas Medicine Stock Performance
NASDAQ:EDIT opened at $3.27 on Wednesday. The company has a 50-day moving average of $4.11 and a 200-day moving average of $5.19. Editas Medicine, Inc. has a 52 week low of $3.22 and a 52 week high of $11.69. The company has a market capitalization of $268.92 million, a price-to-earnings ratio of -1.55 and a beta of 1.99.
Editas Medicine (NASDAQ:EDIT – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.12). Editas Medicine had a negative return on equity of 62.61% and a negative net margin of 288.59%. The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $4.78 million. During the same quarter in the prior year, the business earned ($0.56) EPS. The firm’s revenue for the quarter was down 82.2% on a year-over-year basis. Sell-side analysts forecast that Editas Medicine, Inc. will post -2.97 EPS for the current year.
Editas Medicine Profile
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
See Also
- Five stocks we like better than Editas Medicine
- Using the MarketBeat Dividend Yield Calculator
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Pros And Cons Of Monthly Dividend Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Buy P&G Now, Before It Sets A New All-Time High
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.